Why the study?
Does high-sensitivity cardiac troponin I provide additive clinical value compared with conventional cardiac troponin I for risk stratification in patients with hemodynamically stable acute pulmonary embolism?
Does high-sensitivity cardiac troponin I provide additive clinical value compared with conventional cardiac troponin I for risk stratification in patients with hemodynamically stable acute pulmonary embolism?
Using high-sensitivity troponin I instead of conventional troponin I in hemodynamically stable pulmonary embolism patients does not add clinical value and may lead to risk overestimation.
hs-cTnI should not yet replace cTnI for PE risk stratification; leaves open whether higher-sensitivity assays refine models in prospective studies.
In this study of patients with hemodynamically stable PE, hs-cTnI identified modest elevations in cardiac troponin levels. However, the results did not provide additive clinical value compared with cTnI. These findings suggest that use of hs-cTnI may result in overestimation of the risk in patients with stable PE.
No takes yet. Share an insight, caveat, or question.
Bikdeli et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: